Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy.

Samarium-153 (Sm) is a highly interesting radionuclide within the field of targeted radionuclide therapy because of its favorable decay characteristics. Sm has a half-life of 1.93 d and decays into a stable daughter nuclide (Eu) whereupon β particles [E = 705 keV (30%), 635 keV (50%)] are emitted which are suitable for therapy.

CERN-MEDICIS: A Review Since Commissioning in 2017.

The CERN-MEDICIS (MEDical Isotopes Collected from ISolde) facility has delivered its first radioactive ion beam at CERN (Switzerland) in December 2017 to support the research and development in nuclear medicine using non-conventional radionuclides. Since then, fourteen institutes, including CERN, have joined the collaboration to drive the scientific program of this unique installation and evaluate the needs of the community to improve the research in imaging, diagnostics, radiation therapy and personalized medicine. The facility has been built as an extension of the ISOLDE (Isotope Separator On Line DEvice) facility at CERN.